Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felipe Martinez

Showing results (81-90 of 137) with videos related to

Pageof 14
Sort By:
Lancet (London, England)|August 30, 2022
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trialsMuthiah Vaduganathan, Kieran F Docherty, Brian L Claggett, et al.
Journal of the American College of Cardiology|March 18, 2026
Comparative Prognosis of Chagas and Other CardiomyopathiesRyohei Ono, Kieran F Docherty, Alasdair D Henderson, et al.
Molecular Imaging and Biology|April 16, 2026
Prospective Pilot Study of <sup>11</sup>C-acetate and <sup>18</sup>F-FDG with PET/CT and PET/MRI for Lesion Detection in Multiple MyelomaKristina Yancey, Will Han, Ming Yang, et al.
Journal of Nuclear Medicine Technology|February 10, 2026
PET Imaging in Alzheimer Disease in the Era of Antiamyloid Therapy in the United States: Clinical Utility, Quantification, and Policy LandscapeTy Skyles, Samantha M Bouchal, Anna Giarratana, et al.
European Journal of Heart Failure|May 29, 2021
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trialScott D Solomon, Rudolf A de Boer, David DeMets, et al.
Circulation. Heart Failure|November 17, 2017
Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic CardiomyopathyLi Shen, Felix Ramires, Felipe Martinez, et al.
Nature Medicine|October 6, 2025
Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fractionMuthiah Vaduganathan, Brian L Claggett, Safia Chatur, et al.
Journal of the American College of Cardiology|March 19, 2016
Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS TrialRenato D Lopes, Sergio Leonardi, Benjamin Neely, et al.
Journal of the American College of Cardiology|August 30, 2022
Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart FailureMuthiah Vaduganathan, Brian L Claggett, Pardeep Jhund, et al.
American Heart Journal|September 21, 2015
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trialJose Carlos Nicolau, Deepak L Bhatt, Matthew T Roe, et al.
Pageof 14

Showing results (81-90 of 137) with videos related to

Sort By:
Pageof 14
Lancet (London, England)|August 30, 2022
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trialsMuthiah Vaduganathan, Kieran F Docherty, Brian L Claggett, et al.
Journal of the American College of Cardiology|March 18, 2026
Comparative Prognosis of Chagas and Other CardiomyopathiesRyohei Ono, Kieran F Docherty, Alasdair D Henderson, et al.
Molecular Imaging and Biology|April 16, 2026
Prospective Pilot Study of <sup>11</sup>C-acetate and <sup>18</sup>F-FDG with PET/CT and PET/MRI for Lesion Detection in Multiple MyelomaKristina Yancey, Will Han, Ming Yang, et al.
Journal of Nuclear Medicine Technology|February 10, 2026
PET Imaging in Alzheimer Disease in the Era of Antiamyloid Therapy in the United States: Clinical Utility, Quantification, and Policy LandscapeTy Skyles, Samantha M Bouchal, Anna Giarratana, et al.
European Journal of Heart Failure|May 29, 2021
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trialScott D Solomon, Rudolf A de Boer, David DeMets, et al.
Circulation. Heart Failure|November 17, 2017
Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic CardiomyopathyLi Shen, Felix Ramires, Felipe Martinez, et al.
Nature Medicine|October 6, 2025
Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fractionMuthiah Vaduganathan, Brian L Claggett, Safia Chatur, et al.
Journal of the American College of Cardiology|March 19, 2016
Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS TrialRenato D Lopes, Sergio Leonardi, Benjamin Neely, et al.
Journal of the American College of Cardiology|August 30, 2022
Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart FailureMuthiah Vaduganathan, Brian L Claggett, Pardeep Jhund, et al.
American Heart Journal|September 21, 2015
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trialJose Carlos Nicolau, Deepak L Bhatt, Matthew T Roe, et al.
Pageof 14